Thankyou for viewing my poster at MicroBio! 

Reference list for Introduction:

1.	D. A. Dorward et al., Tissue-specific Immunopathology in Fatal COVID-19. American Journal of Respiratory and Critical Care Medicine,  (2020).
2.	J. A. C. Sterne et al., Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. Jama 324, 1330-1341 (2020).
3.	P. Horby et al., Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med,  (2020).
4.	N. J. Brendish et al., Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study. The Lancet Respiratory Medicine 8, 1192-1200 (2020).
5.	K. Beard et al., Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care ‘test-and-treat’ strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol. BMJ Open 9, e031674 (2019).
6.	J. Legebeke et al., Distinct immune responses in patients infected with influenza or SARS-CoV-2, and in COVID-19 survivors, characterised by transcriptomic and cellular abundance differences in blood. medRxiv, 2021.2005.2012.21257086 (2021).
7.	J. J. Clark et al., Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19. bioRxiv, 2020.2010.2013.334532 (2021).

More details on the work presented can be found here

Figure 1: https://www.atsjournals.org/doi/10.1164/rccm.202008-3265OC
Figure 2: https://www.medrxiv.org/content/10.1101/2021.05.12.21257086v1
Figure 3: Manuscript in preparation
Figure 4: https://www.biorxiv.org/content/10.1101/2020.10.13.334532v1

